Skip to content
Screener

BioCryst Pharmaceuticals BCRX Total Cost of Revenue

Total Cost of Revenue at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.74M-34.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$9.94M+277%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$3M+76.0%
Precigen logo
PrecigenPGEN
$10.64M+20.1%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$28.32M+36.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$3.47M-5.0%

Segments

By segment

See full
Reportable Segment$3.84M+37.2%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
License and other revenues60,73792365,7492,670
Total revenues218,250163,353374,663308,887
Expenses:
Cost of product sales3,8402,7989,2177,366
Acquired in-process research and development697,761
Research and development51,96943,386112,28880,656
Selling, general and administrative63,97687,383158,530169,852
Total operating expenses119,785133,567977,796257,874

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's total cost of revenue?
BioCryst Pharmaceuticals (BCRX) reported total cost of revenue of $3.84M in Q2 2026.
How has BioCryst Pharmaceuticals's total cost of revenue changed year-over-year?
BioCryst Pharmaceuticals's total cost of revenue increased by 37.2% year-over-year, from $2.8M to $3.84M.
What is the long-term trend for BioCryst Pharmaceuticals's total cost of revenue?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's total cost of revenue has grown at a 27.5% compound annual growth rate (CAGR), from $7.23M to $19.08M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about BioCryst Pharmaceuticals's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude